Dopamine D4 receptors may alleviate antipsychotic-induced parkinsonism.
Seeman
P
P
Pharmacology Department, University of Toronto, Canada.
Corbett
R
R
Van Tol
H H
HH
D014150:Antipsychotic Agents / Q000009:adverse effects*; D003024:Clozapine / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D018727:Muscarinic Antagonists; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000517:prevention & control*; D011869:Radioligand Assay; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D050638:Receptors, Dopamine D4; D011976:Receptors, Muscarinic / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists
D014150:Antipsychotic Agents; C493599:DRD4 protein, human; D065127:Dopamine D2 Receptor Antagonists; D018727:Muscarinic Antagonists; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D011976:Receptors, Muscarinic; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D050638:Receptors, Dopamine D4; D003024:Clozapine; D004298:Dopamine